BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnson SW, Brown SV, Priest DH. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure. Clin Infect Dis 2020;71:1133-9. [PMID: 31560051 DOI: 10.1093/cid/ciz966] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Poylin V, Hawkins AT, Bhama AR, Boutros M, Lightner AL, Khanna S, Paquette IM, Feingold DL; Prepared by the Clinical Practice Guidelines Committee of The American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection. Dis Colon Rectum 2021;64:650-68. [PMID: 33769319 DOI: 10.1097/DCR.0000000000002047] [Reference Citation Analysis]
2 Hai Z, Peng Zhen L, Juan M, Fan Y, Jin Rong C, Jing Yao L, Li Xia Z. Extraintestinal Clostridioides difficile infection. IDCases 2020;22:e00921. [PMID: 32923365 DOI: 10.1016/j.idcr.2020.e00921] [Reference Citation Analysis]
3 Fishbein SRS, Hink T, Reske KA, Cass C, Struttmann E, Iqbal ZH, Seiler S, Kwon JH, Burnham CA, Dantas G, Dubberke ER. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients. mSphere 2021;6:e00936-20. [PMID: 33441409 DOI: 10.1128/mSphere.00936-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia J, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild M, Fitzpatrick F, Kuijper EJ; guideline committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021:S1198-743X(21)00568-1. [PMID: 34678515 DOI: 10.1016/j.cmi.2021.09.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hurley JC. Oral Vancomycin Prophylaxis for Clostridioides difficile Infection: Cause or Effect? Clin Infect Dis 2021;73:e2850-1. [PMID: 32948875 DOI: 10.1093/cid/ciaa1424] [Reference Citation Analysis]
6 Babar S, El Kurdi B, El Iskandarani M, Haddad I, Imam Z, Alomari M, Myers J, Moorman J. Oral vancomycin prophylaxis for the prevention of Clostridium difficile infection: A systematic review and meta-analysis. Infect Control Hosp Epidemiol 2020;41:1302-9. [PMID: 32594929 DOI: 10.1017/ice.2020.277] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
7 Cross SJ, Morton TH, Wolf J. Epidemiology, Diagnosis, and Treatment of Clostridioides difficile Infection in Immunocompromised Children. J Pediatric Infect Dis Soc 2021;10:S46-51. [PMID: 34791397 DOI: 10.1093/jpids/piab078] [Reference Citation Analysis]
8 Peled JU, Taur Y. The Detrimental Effects of Oral Vancomycin. Clin Infect Dis 2021;73:e2820-1. [PMID: 33031501 DOI: 10.1093/cid/ciaa1504] [Reference Citation Analysis]
9 Gonzales-luna AJ, Carlson TJ. Follow your Gut: Microbiome-Based Approaches in the Developmental Pipeline for the Prevention and Adjunctive Treatment of Clostridioides difficile Infection (CDI). Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00729-8] [Reference Citation Analysis]
10 Garey KW. Perils, Pitfalls, and Promise of Primary Prophylaxis for Clostridioides difficile Infection. Clin Infect Dis 2020;71:1140-1. [PMID: 31560048 DOI: 10.1093/cid/ciz970] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Yokoyama Y, Shiota A, Asai N, Koizumi Y, Yamagishi Y, Sakanashi D, Nakamura A, Suematsu H, Ohnishi M, Mikamo H. Risk factors of first recurrence of Clostridioides difficile infection. Anaerobe 2022;:102556. [PMID: 35395406 DOI: 10.1016/j.anaerobe.2022.102556] [Reference Citation Analysis]
12 Reigadas E, van Prehn J, Falcone M, Fitzpatrick F, Vehreschild MJGT, Kuijper EJ, Bouza E; European Society of Clinical Microbiology and Infectious Diseases Study Group on Clostridioides difficile (ESGCD) and Study Group for Host and Microbiota interaction (ESGHAMI). How to: prophylactic interventions for prevention of Clostridioides difficile infection. Clin Microbiol Infect 2021:S1198-743X(21)00368-2. [PMID: 34245901 DOI: 10.1016/j.cmi.2021.06.037] [Reference Citation Analysis]
13 Tilton CS, Sexton M, Johnson SW, Gu C, Chen Z, Robichaux C, Metzger NL. Evaluation of a risk assessment model to predict infection with healthcare facility-onset Clostridioides difficile. Am J Health Syst Pharm 2021:zxab201. [PMID: 33954428 DOI: 10.1093/ajhp/zxab201] [Reference Citation Analysis]
14 Episcopia B, Gupta A, Fornek M, Kaminski M, Malik S, Sunny S, Landman D, Xavier G, Quale J. Trends in Healthcare Facility-Onset Clostridioides difficile Infection and the Impact of Testing Schemes in an Acute Care Hospital System in New York City, 2016-2019. Am J Infect Control 2021:S0196-6553(21)00118-8. [PMID: 33716096 DOI: 10.1016/j.ajic.2021.03.003] [Reference Citation Analysis]
15 Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021;116:1124-47. [PMID: 34003176 DOI: 10.14309/ajg.0000000000001278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hurley JC, Brownridge D. Could simulation methods solve the curse of sparse data within clinical studies of antibiotic resistance? JAC Antimicrob Resist 2021;3:dlab016. [PMID: 34223093 DOI: 10.1093/jacamr/dlab016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Adelman MW, Woodworth MH, Shaffer VO, Martin GS, Kraft CS. Critical Care Management of the Patient with Clostridioides difficile. Crit Care Med 2021;49:127-39. [PMID: 33156122 DOI: 10.1097/CCM.0000000000004739] [Reference Citation Analysis]
18 Bogdanová K, Doubravská L, Vágnerová I, Hricová K, Pudová V, Röderová M, Papajk J, Uvízl R, Langová K, Kolář M. Clostridioides difficile and Vancomycin-Resistant Enterococci in COVID-19 Patients with Severe Pneumonia. Life (Basel) 2021;11:1127. [PMID: 34833003 DOI: 10.3390/life11111127] [Reference Citation Analysis]
19 McCort MN, Oehler C, Enriquez M, Landon E, Nguyen CT, Pettit NN, Ridgway J, Pisano J. Universal molecular Clostridioides difficile screening and overtreatment in solid organ transplant recipients. Transpl Infect Dis 2020;22:e13375. [PMID: 32569411 DOI: 10.1111/tid.13375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Tariq R, Laguio-Vila M, Tahir MW, Orenstein R, Pardi DS, Khanna S. Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis. Therap Adv Gastroenterol 2021;14:1756284821994046. [PMID: 33747124 DOI: 10.1177/1756284821994046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]